Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest of Achilles Therapeutics plc from 31 Dec 2019 to 30 Jun 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
Summary
Achilles Therapeutics plc quarterly and annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD history and change rate from 31 Dec 2019 to 30 Jun 2024.
  • Achilles Therapeutics plc Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending 30 Jun 2024 was $16,372,000, a 3% increase year-over-year.
  • Achilles Therapeutics plc annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2023 was $69,174,000, a 2.7% increase from 2022.
  • Achilles Therapeutics plc annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2022 was $71,065,000, a 16% decline from 2021.
  • Achilles Therapeutics plc annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2021 was $61,062,000, a 84% decline from 2020.
Source SEC data
View on sec.gov
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Quarterly Change (%)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Annual (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Annual Change (%)

Achilles Therapeutics plc Quarterly Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q2 2024 $16,372,000 +$508,000 +3% 01 Apr 2024 30 Jun 2024 6-K 14 Aug 2024 2024 Q2
Q2 2023 $16,880,000 +$395,000 +2.3% 01 Apr 2023 30 Jun 2023 6-K 14 Aug 2024 2024 Q2
Q2 2022 $17,275,000 01 Apr 2022 30 Jun 2022 6-K 04 Aug 2023

Achilles Therapeutics plc Annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2023 $69,174,000 +$1,891,000 +2.7% 01 Jan 2023 31 Dec 2023 20-F 04 Apr 2024 2023 FY
2022 $71,065,000 -$10,003,000 -16% 01 Jan 2022 31 Dec 2022 20-F 04 Apr 2024 2023 FY
2021 $61,062,000 -$27,866,000 -84% 01 Jan 2021 31 Dec 2021 20-F 04 Apr 2024 2023 FY
2020 $33,196,000 -$19,206,000 -137% 01 Jan 2020 31 Dec 2020 20-F 07 Mar 2023 2022 FY
2019 $13,990,000 01 Jan 2019 31 Dec 2019 20-F 01 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.